ESG Overview

Overview

The report presents Mankind Pharma's FY 2024-25 ESG performance across seven manufacturing locations and corporate offices. It highlights a 63% renewable share in the total energy mix, 35,743 T CO2eq of total GHG emissions, and a reported 73% carbon reduction from FY21. The company reports 21,325 employees, zero LTIFR, and 14,955 MT of total waste generation, with 93% diverted to recycling, reuse and co-processing. Sustainability oversight sits with the Board-level Risk Management Committee, while BRSR Core indicators received reasonable third-party assurance.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2024-2025
Period: 1 April 2024 – 31 March 2025
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP

Ratings

GRI level

Materiality

Assessment
Basis
Matrix

Assurance

Level
Scope
Statement included
Metrics assured

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services